Published in Transplantation on September 27, 1995
miR-21-mediated tumor growth. Oncogene (2006) 9.90
Fabrication of microfluidic systems in poly(dimethylsiloxane). Electrophoresis (2000) 9.45
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science (2001) 6.84
Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A (2006) 6.33
A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev (1998) 5.14
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A (1999) 4.90
Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell (1998) 4.77
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
The three-dimensional structure of canine parvovirus and its functional implications. Science (1991) 3.87
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology (2004) 3.54
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling. J Biol Chem (2000) 3.26
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84
Fabrication of topologically complex three-dimensional microfluidic systems in PDMS by rapid prototyping. Anal Chem (2000) 2.81
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
Structural basis for self-association and receptor recognition of human TRAF2. Nature (1999) 2.74
Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr Biol (2000) 2.67
Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57
Correlation of the highest-energy cosmic rays with nearby extragalactic objects. Science (2007) 2.57
N-acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiology (2001) 2.51
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50
Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J Exp Med (1998) 2.49
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol (1999) 2.48
Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48
Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J Immunol (1991) 2.46
Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell (2001) 2.43
Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38
Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development. Proc Natl Acad Sci U S A (1997) 2.37
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
A targeted mutation at the known collagenase cleavage site in mouse type I collagen impairs tissue remodeling. J Cell Biol (1995) 2.30
Binding of peptides with basic residues to membranes containing acidic phospholipids. Biophys J (1991) 2.30
Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
The structural basis for the recognition of diverse receptor sequences by TRAF2. Mol Cell (1999) 2.25
Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24
In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol (1998) 2.23
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22
Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22
Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20
Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20
Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother (1998) 2.19
Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19
Pre-injury neuro-psychiatric medication use, alone or in combination with cardiac medications, may affect outcomes in trauma patients. J Postgrad Med (2014) 2.16
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis (1996) 2.12
Morphometric and electron-microscopic analyses of the effects of gonadotropin-releasing hormone agonists on uterine leiomyomas. Arch Pathol Lab Med (1998) 2.11
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09
The side effects of FK 506 in humans. Transplant Proc (1990) 2.08
Trisomy eight in ES cells is a common potential problem in gene targeting and interferes with germ line transmission. Dev Dyn (1997) 2.05
Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04
Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant (2014) 2.00
Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis. Proc Natl Acad Sci U S A (2001) 2.00
Functional expression of Drosophila para sodium channels. Modulation by the membrane protein TipE and toxin pharmacology. J Gen Physiol (1997) 1.99
Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99
Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation (1991) 1.95
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94
Human allograft acceptance is associated with immune regulation. J Clin Invest (2000) 1.94
Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94
Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv (2001) 1.93
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res (2001) 1.93
Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int J Tuberc Lung Dis (2010) 1.92
The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol (1998) 1.91
Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl (2000) 1.88
Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol (1996) 1.88
Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88
PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr Biol (2001) 1.86
Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 1.86
Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry (2001) 1.86
Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest (1997) 1.86
Experience with liver and kidney allografts from non-heart-beating donors. Transplantation (1995) 1.83
Orthotopic liver transplantation in the mouse. Transplantation (1991) 1.82
Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81
Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc (1990) 1.80